ABSTRACT

Introduction

Ovarian cancer typically presents at an advanced stage and while initial chemotherapy response rates are favorable, a majority of patients experience recurrence with the subsequent development of chemoresistance. Recurrent, platinum-resistant disease is associated with a very poor prognosis as treatment in this setting is often limited by systemic toxicity. Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target antigens specific to ovarian tumor cells with direct delivery of cytotoxic agents to combat recurrent, platinum-resistant disease while limiting systemic toxicity.

Areas covered

The basic structure and function of ADCs will be reviewed as well as the current data on ADCs under investigation in ovarian cancer.

Expert opinion

ADCs represent a promising class of targeted therapy in recurrent ovarian cancer with excellent response rates particularly when utilized as combination therapy. While mirvetuximab soravtansine is the only ADC that has been evaluated in a phase 3 trial, many other ADCs and trials are on the horizon. As the field of targeted therapy continues to evolve, continued development of target antigens and ADCs are likely to represent a key development in treatment of recurrent, platinum-resistant disease.

中文翻译：

---

用于治疗卵巢癌的抗体-药物缀合物

摘要

介绍

卵巢癌通常出现在晚期，虽然最初的化疗反应率良好，但大多数患者会因随后出现化疗耐药而出现复发。复发性铂耐药疾病与非常差的预后相关，因为这种情况下的治疗通常受到全身毒性的限制。抗体药物偶联物 (ADC) 是新型治疗剂，旨在针对卵巢肿瘤细胞特异性抗原，直接递送细胞毒性药物，以对抗复发性铂类耐药疾病，同时限制全身毒性。

覆盖领域

将回顾 ADC 的基本结构和功能，以及正在研究的卵巢癌 ADC 的当前数据。

专家意见

ADC 代表了一类很有前景的复发性卵巢癌靶向治疗，具有出色的缓解率，特别是在用作联合治疗时。虽然 mirvetuximab soravtansine 是唯一在 3 期试验中进行评估的 ADC，但许多其他 ADC 和试验也即将推出。随着靶向治疗领域的不断发展，靶抗原和 ADC 的持续开发可能代表复发性铂类耐药疾病治疗的关键进展。